BRPI0409918A - composição farmacêutica na forma de um hidrogel para administração transdérmica de ingredientes ativos - Google Patents

composição farmacêutica na forma de um hidrogel para administração transdérmica de ingredientes ativos

Info

Publication number
BRPI0409918A
BRPI0409918A BRPI0409918-4A BRPI0409918A BRPI0409918A BR PI0409918 A BRPI0409918 A BR PI0409918A BR PI0409918 A BRPI0409918 A BR PI0409918A BR PI0409918 A BRPI0409918 A BR PI0409918A
Authority
BR
Brazil
Prior art keywords
hydrogel
pharmaceutical composition
active ingredients
transdermal delivery
relates
Prior art date
Application number
BRPI0409918-4A
Other languages
English (en)
Inventor
Patrick Franke
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33395772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0409918A publication Critical patent/BRPI0409918A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA NA FORMA DE UM HIDROGEL PARA ADMINISTRAçãO TRANSDéRMICA DE INGREDIENTES ATIVOS". A invenção refere-se a uma composição farmacêutica na forma de um hidrogel que compreende um diéster de ácido carbónico, um C~ 2~-C~ 4~ álcool alquílico, uma substância ativa e uma matriz polimérica. A invenção também refere-se ao uso de um éster de ácido carbónico como um agente de permeação transdérmica para uma substância ativa em uma composição farmacêutica na forma de um hidrogel, a referida composição compreende uma matriz polimérica e um C~ 2~-C~ 4~ álcool alquílico. A invenção também refere-se a uma composição resistente ao suor na forma de um hidrogel, a qual compreende um polímero acrílico em combinação com um derivado de celulose.
BRPI0409918-4A 2003-04-28 2004-04-21 composição farmacêutica na forma de um hidrogel para administração transdérmica de ingredientes ativos BRPI0409918A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03008856 2003-04-28
PCT/EP2004/004224 WO2004096191A1 (de) 2003-04-28 2004-04-21 Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen

Publications (1)

Publication Number Publication Date
BRPI0409918A true BRPI0409918A (pt) 2006-04-25

Family

ID=33395772

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409918-4A BRPI0409918A (pt) 2003-04-28 2004-04-21 composição farmacêutica na forma de um hidrogel para administração transdérmica de ingredientes ativos

Country Status (33)

Country Link
EP (2) EP1875905B1 (pt)
JP (2) JP4829102B2 (pt)
KR (1) KR101093999B1 (pt)
CN (1) CN1780610B (pt)
AR (1) AR044113A1 (pt)
AT (2) ATE467412T1 (pt)
AU (1) AU2004233572B2 (pt)
BR (1) BRPI0409918A (pt)
CA (1) CA2523734C (pt)
CL (1) CL2004000884A1 (pt)
CO (1) CO5640075A2 (pt)
CR (1) CR8059A (pt)
CY (1) CY1108069T1 (pt)
DE (2) DE502004011164D1 (pt)
DK (1) DK1617827T3 (pt)
EA (1) EA008686B1 (pt)
EC (1) ECSP056186A (pt)
ES (2) ES2300763T3 (pt)
HK (1) HK1087633A1 (pt)
HR (1) HRP20080178T3 (pt)
JO (1) JO2492B1 (pt)
MX (1) MXPA05011541A (pt)
NO (1) NO20055601L (pt)
NZ (2) NZ543264A (pt)
PE (1) PE20050461A1 (pt)
PL (1) PL1617827T3 (pt)
PT (1) PT1617827E (pt)
RS (1) RS51307B (pt)
SI (1) SI1617827T1 (pt)
TW (1) TWI343259B (pt)
UA (1) UA83036C2 (pt)
WO (1) WO2004096191A1 (pt)
ZA (1) ZA200509549B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506141D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
GB0506139D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
DE102005035879A1 (de) * 2005-07-30 2007-02-01 Paul Hartmann Ag Hydrogel
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
PL2702982T3 (pl) * 2011-04-25 2017-07-31 Jun-Hyoung Park Kompozycja do miejscowego stosowania do zapobiegania wypadaniu włosów i stymulowania porostu włosów
FR2976808B1 (fr) * 2011-06-22 2013-06-28 Urgo Lab Composition filmogene et son utilisation pour le traitement de l'herpes
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
DE102018213754A1 (de) * 2018-08-15 2020-02-20 Henkel Ag & Co. Kgaa "Tris(hydroxymethyl-)aminomethan oder seine Salze als Wirkstoff zur Reduzierung der Schweißsekretion“

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1182229B (de) 1960-11-16 1964-11-26 Upjohn Co Verfahren zur Herstellung von 7-Methylsteroiden
US3341557A (en) 1961-06-05 1967-09-12 Upjohn Co 7-methyltestosterones
US3924004A (en) 1971-11-24 1975-12-02 Syntex Corp Fatty alcohol-propylene carbonate-glycol solvent cream vehicle
US4000273A (en) 1973-11-01 1976-12-28 Richardson-Merrell Inc. Method for the control of fertility
JPS5540604A (en) * 1978-09-14 1980-03-22 Mitsui Toatsu Chem Inc Improved local topicum
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
JPS5970612A (ja) * 1982-10-13 1984-04-21 Nippon Redarii Kk ゲル軟膏基剤
ATE72129T1 (de) * 1987-05-27 1992-02-15 Burghart Kurt Transdermal therapeutisch wirkende pharmazeutische zubereitung sowie vorrichtung zum aufbringen der zubereitung.
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
KR950701508A (ko) * 1992-06-11 1995-04-28 챨스 디 에버트 경피식 약물수송을 조절하기 위한 글리세린의 용도(the use of glycerin in moderating transdermal drug delivery)
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
WO1996008255A1 (en) 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Transdermal device for delivery of levonorgestrel
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
JPH09194396A (ja) 1996-01-17 1997-07-29 Pola Chem Ind Inc 貼付剤用マトリックス
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
US5736128A (en) * 1996-05-14 1998-04-07 Isp Investments Inc. Cosmetic composition for rejuvenation of skin without skin irritation
EP0954260A1 (en) 1996-05-22 1999-11-10 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US20020012694A1 (en) 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
WO1999067271A1 (en) 1998-06-19 1999-12-29 Akzo Nobel N.V. Testosterone derivative
FR2781666B1 (fr) * 1998-07-30 2000-09-08 Oreal Composition cosmetique solide et ses utilisations
JP2935113B1 (ja) * 1998-09-24 1999-08-16 小林製薬株式会社 インドメタシン経皮吸収剤
AU2003600A (en) 1999-01-13 2000-08-01 Taisho Pharmaceutical Co., Ltd. External steroid preparation
JP2000264899A (ja) * 1999-01-13 2000-09-26 Taisho Pharmaceut Co Ltd ステロイド外用剤
JP2001139451A (ja) * 1999-11-17 2001-05-22 Lion Corp ジェル状化粧料
CA2431328A1 (en) 2000-12-15 2002-06-20 Akzo Nobel Nv 14(15)-unsaturated 15- and/or 16- substituted androgens with mixed androgen-progestational profile
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
DE10107663B4 (de) 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
ZA200509549B (en) 2007-02-28
EA200501583A1 (ru) 2006-06-30
HK1087633A1 (en) 2006-10-20
PT1617827E (pt) 2008-04-30
EP1617827B1 (de) 2008-02-13
ES2345458T3 (es) 2010-09-23
MXPA05011541A (es) 2006-05-31
UA83036C2 (ru) 2008-06-10
KR20060007403A (ko) 2006-01-24
EP1875905B1 (de) 2010-05-12
NZ583760A (en) 2011-10-28
HRP20080178T3 (en) 2008-05-31
CL2004000884A1 (es) 2005-03-11
CA2523734C (en) 2009-12-22
AR044113A1 (es) 2005-08-24
ATE385786T1 (de) 2008-03-15
SI1617827T1 (sl) 2008-06-30
CR8059A (es) 2006-05-29
JP2010241824A (ja) 2010-10-28
TW200524644A (en) 2005-08-01
JP2006524653A (ja) 2006-11-02
EP1875905A3 (de) 2008-06-25
NO20055601D0 (no) 2005-11-25
NO20055601L (no) 2006-01-26
CN1780610B (zh) 2010-06-09
CA2523734A1 (en) 2004-11-11
TWI343259B (en) 2011-06-11
JO2492B1 (en) 2009-10-05
PL1617827T3 (pl) 2008-07-31
EP1875905A2 (de) 2008-01-09
CN1780610A (zh) 2006-05-31
AU2004233572B2 (en) 2010-07-15
DK1617827T3 (da) 2008-06-02
CY1108069T1 (el) 2014-02-12
EA008686B1 (ru) 2007-06-29
EP1617827A1 (de) 2006-01-25
WO2004096191A1 (de) 2004-11-11
ES2300763T3 (es) 2008-06-16
DE502004011164D1 (de) 2010-06-24
JP4829102B2 (ja) 2011-12-07
ATE467412T1 (de) 2010-05-15
AU2004233572A1 (en) 2004-11-11
ECSP056186A (es) 2006-04-19
CO5640075A2 (es) 2006-05-31
NZ543264A (en) 2010-03-26
DE502004006196D1 (de) 2008-03-27
PE20050461A1 (es) 2005-08-13
RS20050809A (en) 2007-09-21
RS51307B (sr) 2010-12-31
KR101093999B1 (ko) 2011-12-15

Similar Documents

Publication Publication Date Title
US20210015740A1 (en) Topical cannabinoid compositions, delivery systems, and uses for pain relief
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
BRPI0416042A (pt) composição e aparelho para suprimento transdérmico
BRPI0519748A2 (pt) preparaÇço de curativo para resfriamento tàpico
DE69940735D1 (de) Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
FR2889811B1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
CL2003002277A1 (es) Composicion farmaceutica inyectable, de deposito de liberacion prolongada, que comprende un agente beneficioso disuelto o disperso en un gel constituido por un polimero bioerosionable y biocompatible; y un solvente.
BRPI0618918B8 (pt) uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
BRPI0517640A (pt) composições farmacêuticas tópicas contendo um composto antiacne e um composto antibiótico
ECSP056186A (es) Composición farmacéutica en forma de hidrogel para administración transdérmica de sustancias activas
AR052545A1 (es) Suspension no acuosa inyectable
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
DE69919863D1 (de) Stabilgelmischung in form einer mischung eines öligen gels und eines wässrigen gels
DE602006016127D1 (de) Zusammensetzung und dosierform mit einer festen oder halbfesten matrix
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
US20190254999A1 (en) Topical composition and delivery system and its use
BRPI0611526A2 (pt) composição tópica contendo gelatina
BRPI0504082A (pt) emulsões refrescantes medicinais
BRPI0407529A (pt) uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática
BRPI0606932A2 (pt) formulação, forma de dosagem, e, uso de uma quantidade terapeuticamente efetiva de uma formulação

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A E 10A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A E 16A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.